Top 25 Fastest Growing Healthcare & Life Science Companies in Asia in 2026

Asia’s healthcare and life sciences growth is becoming easier to see in real-world care. 

Hospital groups are expanding capacity, specialty treatment is growing in areas such as cardiology, oncology, neurology and gastroenterology and more companies are building the tests, tools and services that support diagnosis and treatment. 

EY’s Q2FY26 report detailed plans for major hospital expansion in India, including about 4,200 beds over five years for the Aster DM Healthcare-Quality Care India platform and about 2,000 beds over five years for Narayana Hrudayalaya. The same report also pointed to stronger revenue coming from more specialized care, with Quality Care India’s CONGO specialties accounting for about 60% of total revenue.

Some of Asia’s faster growing healthcare markets also sit on a relatively strong care infrastructure. In South Korea, for example, the entire population is covered for a core set of health services, and the country has 12.6 hospital beds per 1,000 people and 87 CT, MRI and PET units per million people, both above OECD averages. The country appears prominently in segments such as diagnostics, medtech and digital health.

Asia’s healthcare and life sciences growth is not coming from a single model or one type of company. This breadth of innovation has garnered companies across Asia a place in the Financial Times’ and Statista’s 2026 High-Growth Asia-Pacific Companies ranking, which includes companies working in genomics, AI software, hospital networks, fertility care, staffing and commercialization support, and not just drug development. 

Let’s take a closer look at the top 25 fastest growing healthcare companies in Asia.

1. CytoGen (FT Rank: 9)

Founded in 2010, South Korea-based CytoGen develops liquid biopsy technologies and services centered on circulating tumor cell analysis, with applications spanning biomarker discovery, companion diagnostics and precision medicine. Revenue reached $8 million in 2024, and the company had 50 employees.

2. SillaJen (FT Rank: 25)

SillaJen is a South Korean biotechnology company developing oncolytic virus immunotherapies for cancer. The company reported $2.88 million in 2024 revenue and had 45 employees. Its pipeline remains focused on engineered viral immunotherapy candidates for oncology, keeping its business centered on drug development rather than commercial-scale product sales.

3. Vuno (FT Rank: 38)

Vuno develops AI-based medical software in South Korea across imaging, biosignals, pathology and speech analysis. The company generated $18.97 million in 2024 revenue and employed 160 people. In February 2026, Vuno said full-year 2025 revenue rose to around $231 million ($34.8 billion won), up from approximately $171 million ($25.9 billion won) in 2024, as growth in key products helped narrow operating losses.

4. 3billion (FT Rank: 42)

South Korea’s 3billion focuses on rare disease genetic testing and variant interpretation. It reported $4.23 million in 2024 revenue and had 85 employees. In December 2025, the company said it had expanded exports to more than 75 countries and reached $3 million in annual export sales, underscoring its international push in rare disease diagnostics.

5. SCL Science (FT Rank: 47)

SCL Science operates in South Korea’s digital healthcare and bio-data services market, connecting diagnostics, data and healthcare platforms. The company reported $3.47 million in 2024 revenue and had 63 employees. In March 2025, it acquired affiliate SCL Healthcare. Later that year, it bought a 60% stake in Pentamedix, now Neogenlogic, as part of its move into cancer vaccine development and its work on the AI platform DeepNeo.

6. Ivim (FT Rank: 75)

Ivim develops intravital microscopy systems in South Korea for real-time imaging in live-animal and preclinical research settings. Revenue came to $2.61 million in 2024, and the company had 35 employees. Its imaging platforms are used in tumor, immune and drug research.

7. PeopleBio (FT Rank: 77)

South Korea’s PeopleBio develops diagnostics focused on protein misfolding diseases, including blood-based testing linked to Alzheimer’s disease research. The company reported $2.74 million in 2024 revenue and had 60 employees. Its portfolio includes multimer detection system technology and oligomerized beta-amyloid testing.

8. Lameditech (FT Rank: 78)

Lameditech is a South Korean medical device company focused on laser-based blood collection and related sampling technologies. It posted $4.82 million in 2024 revenue and had 57 employees. The company’s core business centers on minimally invasive blood collection systems designed to reduce discomfort during sampling.

9. Seers (FT Rank: 82)

Seers develops remote patient monitoring and telemedicine technology in South Korea, including wearable biosensors, monitoring platforms and medical AI. It reported $5.94 million in 2024 revenue and had 94 employees in the FT data, while their Q4 2025 report showed 144 employees as of January 2026. In February 2026, Seers said 2025 revenue climbed to around $32 million from $5.3 million (KRW 48.17 billion from KRW 8.0 billion) in 2024, alongside its first full-year operating profit.

10. Graphy (FT Rank: 103)

Graphy is a South Korean dental technology company focused on direct 3D-printed aligners, shape-memory materials and related orthodontic products. The company reported $11.83 million in 2024 revenue and had 107 employees. Its business is built around digital orthodontics and dental materials, and in early 2026, it said it was accelerating expansion in the US.

Related: Top 3 Medtech Companies to Work for in Asia in 2026, Per Financial Times

11. Dx&Vx (FT Rank: 123)

South Korea’s Dx&Vx works across vaccines, diagnostics and biotechnology research. Revenue reached $24.9 million in 2024, and the company had 121 employees. In 2025, Dx&Vx highlighted patent activity tied to anti-obesity and mRNA cancer vaccine candidates, and in July, it announced a $220 million co-development and licensing agreement with a US biotech company for an mRNA cancer vaccine program.

12. MitoCharge (FT Rank: 125)

Singapore-based MitoCharge, developed by QuantumTX, centers on non-invasive muscle activation and recovery systems that combine magnetic stimulation and phototherapy. The company reported $1.7 million in 2024 revenue and had 6 employees. Its technology is used across wellness, rehabilitation and eldercare settings.

13. Medikigai (FT Rank: 137)

Medikigai is an India-based healthcare services company providing revenue cycle management and reimbursement support for medical practices. It reported $5.77 million in 2024 revenue and had 210 employees. Its service mix spans billing, coding and claims operations aimed at helping providers manage back-office and payment workflows.

14. ASG Eye Hospital (FT Rank: 138)

India’s ASG Eye Hospital operates a specialty ophthalmology network offering cataract, retina, glaucoma, pediatric and other eye care services. The company reported $133.02 million in 2024 revenue and had 6,000 employees. By 2030, ASG plans to invest around $160 million to $210 million (₹15 billion to ₹20 billion) to expand its eye care network across India. The company has appointed four banks for a proposed FY27 IPO that is expected to raise approximately $330 million to $475 million (₹3,000 crore to ₹4,000 crore).

15. iX Biopharma (FT Rank: 178)

iX Biopharma is a Singapore specialty pharmaceutical company focused on drug delivery and therapies for pain and other chronic conditions. It reported $4.46 million in 2024 revenue and had 59 employees. For the six months ended December 31, 2025, the company reported 1H FY2026 revenue of $15.9 million, with nutraceutical revenue rising 170%.

16. Bio-Nanosciences (FT Rank: 275)

Malaysia’s Bio-Nanosciences develops and markets health supplements and consumer wellness products under the Swissmed brand. Revenue totaled $4.38 million in 2024, and the company had 12 employees. Its business spans product development, formulation and wellness branding.

17. Beyond Medical (FT Rank: 280)

Beyond Medical is a Singapore healthcare group supporting a portfolio of specialist clinics, aesthetics clinics, a general practitioner clinic, day-surgery facilities and regional affiliated offices. The company reported $28.57 million in 2024 revenue and had 100 employees. Its operations are centered on private care delivery and clinic-network services.

18. Connect Staffing (FT Rank: 297)

Australia’s Connect Staffing provides workforce solutions for healthcare, aged care and related service settings. It reported $15.96 million in 2024 revenue and had 21 employees. The company’s service model focuses on staffing support for providers managing workforce shortages and ongoing care delivery demands.

19. Oasis Fertility (FT Rank: 344)

Oasis Fertility is an India-based fertility care network offering IVF, IUI, ICSI and other assisted reproduction services through clinics across multiple cities. The company reported $28.19 million in 2024 revenue and had 751 employees. A March 2026 company database profile listed annual revenue of about $25.2 million (₹238 crore) as of March 31, 2025.

20. Royce Dental Group (FT Rank: 356)

Royce Dental Group is a Singapore dental care provider offering general dentistry alongside specialist treatment through a broad clinic network. The company reported $35.89 million in 2024 revenue and had 336 employees. Its public-facing materials describe more than 20 clinics across Singapore and a one-stop model spanning routine and specialist dental services.

Related: Top 30 Largest Publicly Traded Healthcare Companies in 2026 by Employee Number

21. Recovery International (FT Rank: 388)

Japan’s Recovery International provides home-visit nursing and rehabilitation services for patients receiving care outside hospital settings. It reported $13.5 million in 2024 revenue and had 280 employees. 

22. Indegene (FT Rank: 414)

Indegene is an India-based digital commercialization company serving biopharma, biotech and medical device clients across medical, clinical and commercial functions. The company reported $339.34 million in 2024 revenue and had 4,961 employees. In Q3 FY26, it reported revenue of $106.1 million (INR 9,421 million), up 30.8% year over year, and completed the acquisitions of Warn & Co. and BioPharm.

23. Bio-Science Marketing (FT Rank: 448)

Malaysia’s Bio-Science Marketing is an OEM and ODM partner for food and health supplements, supporting formulation, branded ingredients and finished-product development. It reported $8.97 million in 2024 revenue and had 47 employees. Its services focus on manufacturing and commercialization support for wellness and supplement brands.

24. Asahi Intecc (FT Rank: 453)

Asahi Intecc is a Japan-based medical device manufacturer known for guidewires and other products used in catheter-based and minimally invasive procedures, alongside device components. The company reported $792.94 million in 2024 revenue and had 9,371 employees. In the six months ended December 31, 2025, sales increased 15.9% year over year to around $448 million (JPY 71,266 million), and the company raised its full-year forecast.

25. IHH Healthcare Singapore (FT Rank: 474)

IHH Healthcare Singapore is part of IHH Healthcare, one of Asia’s largest private healthcare groups, operating hospitals and specialist care facilities. It reported $1,395.71 million in 2024 revenue and had 6,139 employees. The company is part of a regional network spanning Singapore, Malaysia, India and other markets, focused on hospital-based and specialty care.

If you want your company to be featured on Xtalks.com, please email [email protected].